On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL…
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in CanadaLONDON…
Founded by Former NHL Player and mental health advocate Daniel Carcillo, the Portland center is the first of its kind…
LAKELAND, Fla., March 19, 2025 (GLOBE NEWSWIRE) -- Lipozem is a weight loss supplement crafted to support burning fat without…
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapiesNew York, New York--(Newsfile Corp. - March 18,…
Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP marketATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics,…
NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and…
NEW YORK--(BUSINESS WIRE)--InTandem Capital Partners (“InTandem Capital” or the “Firm”), a healthcare services-focused private equity firm, announced today that it…
Largest shareholder, CK Life Sciences Int’l., (Holdings) Inc. agrees to conversion of debt into equity, removing all existing debt from…
MINNEAPOLIS, MN, March 12, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company or FOXO”), provides an update on Myrtle…